The first deal by any fund is always scrutinised carefully, both within the company and without. So, UK-listed drugs company GlaxoSmithKline’s (GSK) new strategic corporate venturing fund for bioelectronic medicines and technologies’ decision to invest in the $27m round for SetPoint Medical offers plenty of opportunities for reading the tea leaves, as it were.
Of interest for “why this deal?” is the background of Imran Eba, who moved over this month after nearly two years as director of the drugs…
